SBE4-beta-cyclodextrin

structure given in first source

Also Known As:

Captisol; SBE-beta-CD; SBE4-beta-CD; betadex sulfobutyl ether sodium; sulfobutyl ether beta-cyclodextrin; sulfobutylether-beta-cyclodextrin; sulfobutylether-betaCD; sulfurbutylether-beta-cyclodextrin; sulphobutylether-betaCD

Networked: 11 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclodextrins: 1345
    - beta-Cyclodextrins: 8
      - SBE4-beta-cyclodextrin: 11
Carbohydrates: 22023
- Polysaccharides: 15383
  - Glucans: 1624
    - Starch: 3882
      - Dextrins: 152
        Cyclodextrins: 1345
        beta-Cyclodextrins: 8
        SBE4-beta-cyclodextrin: 11
- Dietary Carbohydrates: 706
  - Starch: 3882
    - Dextrins: 152
      - Cyclodextrins: 1345
        beta-Cyclodextrins: 8
        SBE4-beta-cyclodextrin: 11

Experts

1.	Fukagawa, Masafumi: 1 article (01/2022)
2.	Isozaki, Yudai: 1 article (01/2022)
3.	Isozumi, Konomi: 1 article (01/2022)
4.	Ito, Jun: 1 article (01/2022)
5.	Kawaji, Atsuro: 1 article (01/2022)
6.	Kimura, Moritsugu: 1 article (01/2022)
7.	Toya, Tomoyuki: 1 article (01/2022)
8.	Barooah, Nilotpal: 1 article (01/2019)
9.	Bhasikuttan, Achikanath C: 1 article (01/2019)
10.	Chatterjee, Suchandra: 1 article (01/2019)

Related Diseases

1.	Kidney Diseases (Kidney Disease) 11/01/2022 - "There is concern that an excipient in Veklury (Gilead's proprietary name for remdesivir) called sulfobutylether-beta-cyclodextrin (SBECD), which is renally cleared, may accumulate and reach toxic levels in patients with advanced kidney disease. "
2.	Renal Insufficiency (Renal Failure) 06/01/2012 - "Voriconazole's intravenous formulation with sulfobutylether beta-cyclodextrin (SBECD) is restricted in patients with renal insufficiency. " 01/01/2022 - "However, in cases of kidney failure, remdesivir administration should be considered only if the therapeutic benefits outweigh the risks because of concern about the accumulation of its solubilizing excipient sulfobutylether-beta-cyclodextrin and subsequent renal tubular injury or liver injury. "
3.	Neoplasms (Cancer) 01/01/2019 - "Supramolecular Nanorods of (N-Methylpyridyl) Porphyrin With Captisol: Effective Photosensitizer for Anti-bacterial and Anti-tumor Activities." 07/15/2005 - "Tumor-bearing mice (n = 12 or 15 per group) were treated with vehicle (Captisol or buffer), erlotinib (orally, 50 mg/kg/d), pertuzumab (i.p. "
4.	Seizures (Absence Seizure) 06/01/2013 - "We have developed a solubilized TPM formulation using a cyclodextrin matrix, Captisol with the long-term goal of evaluating its safety and efficacy in neonatal seizures. "
5.	Multiple Myeloma 05/01/2016 - "Coagulation factor IX (recombinant), albumin fusion protein (Idelvion) for hemophilia B; captisol-enabled melphalan hydrochloride (Evomela) for multiple myeloma; and antihemophilic factor (recombinant) (Kovaltry) for hemophilia A. "

Related Drugs and Biologics

1.	Excipients (Suspending Agents)
2.	remdesivir
3.	Voriconazole (Vfend)
4.	Erlotinib Hydrochloride (CP 358,774)
5.	Photosensitizing Agents (Photosensitizers)
6.	Urethane (Ethyl Carbamate)
7.	Proteins (Proteins, Gene)
8.	Porphyrins
9.	Melphalan (Alkeran)
10.	Factor IX (Coagulation Factor IX)

Related Therapies and Procedures

1.	Hemodiafiltration
2.	Renal Dialysis (Hemodialysis)